RxDoctor Payments Data

Frank Savoretti, MD

Internal Medicine · Johnston, RINPI 1750377149

Payments from drug & device makers

$1,420in general payments, 2019–2025

Across 65 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$343
  • GSK$223
  • Lilly USA, LLC$163
  • Boehringer Ingelheim$147
  • Gilead$100
  • Exact Sciences$70
  • plus $374 from 12 others

What the payments were for

  • Food & beverage$1,40599%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,420 in reported general payments places this provider in the 80th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$50,246
Medicare patients
173
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$100,198
XareltoRivaroxaban24$32,122
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$24,073
DuleraMometasone/Formoterol18$8,827
Omeprazole548$8,074
SymbicortBudesonide/Formoterol Fumarate21$7,540
Atorvastatin Calcium642$7,107
Qvar RedihalerBeclomethasone Dipropionate13$6,489
Breo ElliptaFluticasone/Vilanterol13$4,986
Albuterol Sulfate HfaAlbuterol Sulfate186$4,723
Levothyroxine Sodium348$4,236
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine92$3,809
Fluticasone Propionate130$3,688
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$3,521
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide373$3,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$100,198105 claims
GSKTrelegy Ellipta, Breo Ellipta$223$29,05936 claims
AstraZenecaSymbicort$343$7,54021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Johnston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →